Novo slashed prices to compete with Lilly. That’s the power of the market: lower costs and better drugs. Price controls do neither — they kill innovation and hurt patients in the long run. https://t.co/F7rInUztfl

Great new @MakingMedPod episode with @SenThomTillis diving into drug pricing reforms, MFN, investment in U.S. biotech, regulatory certainty, and the forces shaping American innovation:

The new U.S.-U.K. trade deal makes Britain’s NHS pay more for cutting-edge drugs in exchange for tariff relief. It’s about time other countries pitched in their fair share. https://t.co/u8cJi63FlV

⛑️NOTHING TO SEE, JUST A “THROWAWAY” MICROCAP. Forbes quietly connects the dots: NextNRG ($NXXT) plus Amazon ( $AMZN ) plus Kroger ( $KR ) in one feature on energy and the food chain. According to Forbes, NextNRG (NXXT) already provides fueling services and trucking support for

Price controls don’t just hit drug companies — they hit patients. After the IRA, funding for new small-molecule drugs dropped almost 70%. That means fewer cures and fewer options when we get sick. https://t.co/8V0ILPPDA7

Medicare can’t save money by buying cheap medical gear that harms patients. A smarter bidding system must weigh real-world costs — including worse outcomes from low-quality equipment. https://t.co/LYdOqMfl6x

California wants a 5% wealth tax to fund health care. If you want to know how that ends, look at Norway: its rich fled, revenue plunged, and the tax raised a fraction of what was lost. https://t.co/lJ0GleN44C

States say they’re using "their own money" to give Medicaid to illegal immigrants. But that’s only possible because the federal government sends them matching dollars — and they inflate those dollars with clever tax tricks. It’s a funding loophole, not generosity.

Americans deserve market-based reforms that make health care affordable again. Tune in to hear a few ideas: https://t.co/DFIuim69cd

Lenders can more easily work with state and local agencies to find grants and programs that may help borrowers afford a home thanks to our streamlined resources. Learn how.

Republicans should put together a health package that includes 340B reform. Experts have been warning about lax 340B oversight for years. https://t.co/Kq2CYGzqQl

Price-controls and "most-favored nation" won't lower drug costs as fast as free-market competition does. Markets, not mandates, bring results. https://t.co/F7rInUztfl

Worried drug patents keep prices high? Look closer. "Monopolies" last just 12-15 years, and that clock starts before the drug even launches. Then generics flood in: first one drops prices by 39%, the next another 15%, and the fall keeps going. https://t.co/8V0ILPPDA7

96% of @USGAO's fake applications got approved for ACA subsidized plans. Now we know why insurance giants are scrambling to extend the credits. https://t.co/Vx4kHcje4C

Trump’s first three Cabinet meetings feature more press questions and answers than all of Biden’s

"A 'Billionaire Tax' Will Only Worsen the Golden State's Health System," writes PRI's @SallyPipes. Read more here: https://t.co/qRitc1Ep9M

If we want affordable drugs, we need more competition -- not more government. More competition = companies forced to cut prices and improve products. https://t.co/F7rInUztfl

Trump wants to lower drug prices. One simple way: cut out the middlemen and let companies sell directly to patients. https://t.co/w8eeq7pxLx

History is clear: competition drives prices down sustainably. Coercive government tactics don’t — and they harm innovation along the way. https://t.co/F7rInUztfl

Excellent column from @AdamMossoff: anti-patent groups are selling Congress a story built on bad data. Generics dominate 90% of prescriptions, U.S. prices are lower than peer nations, and FDA/USPTO records don’t match activists’ claims. Weakening patents won’t lower costs — it

Patents aren't the villain -- they're the engine behind the GLP-1 revolution. We're already seeing fierce competition push prices lower: Wegovy's price has dropped more than 85% since it was first released. Undermining patents would only mean fewer future breakthroughs for

California's wealth tax proposal looks like a bold fix — until you remember the rich can simply pack their bags and leave. What happens to the state's tax base then? https://t.co/lJ0GleN44C

Auditors at @USGAO submitted 24 fake applications for subsidized ACA plans. 23 were approved. And Democrats still want to extend the subsidies anyway. https://t.co/r9bOJSuPeq